Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy

سال انتشار: 1399
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 429

فایل این مقاله در 13 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-23-8_014

تاریخ نمایه سازی: 27 مرداد 1399

چکیده مقاله:

Objective(s): Program death 1 (PD-1)/ program death-ligand 1 (PD-L1) pathways, as the main inhibitory checkpoints, induce immunosuppression in the tumor microenvironment (TME). Despite the importance of inhibitor checkpoint receptor (ICR) blockers, their outcomes have been limited by the low immune response rate and induced acquired resistance. Pre-existing tumor-specific T cells is related to the improvement of their therapeutic efficacy. In the present study, we show that the combination of liposomal gp100 nanovaccine with anti PD-1 monoclonal antibody (mAb) potentiates the therapeutic effect in the melanoma model.Materials and Methods: In this study, we first decorate the cationic liposome with gp10025-33 self-antigen and then characterize it. Mice bearing B16F10 melanoma tumors were vaccinated with different formulations of gp100 peptide (free or liposomal form) with or without CpG ODN adjuvant in combination with anti PD-1 mAb.Results: Therapeutic combination of liposomal nanovaccine and CpG with anti PD-1 mAb, demonstrated the increased number of tumor infiltrated lymphocytes (TILs) in TME with the highest IFN-γ production and cytotoxic activity, which led to remarkable tumor regression. Conclusion: Our results demonstrated the synergism between Lip-peptide+CpG nanovaccine and anti PD-1 regime, which improved the therapeutic efficacy of PD-1 checkpoint blocker in melanoma mice models.

کلیدواژه ها:

Anti PD ، 1 monoclonal ، antibody CpG ODN GP100 Liposome Melanoma

نویسندگان

Mona Yazdani

Department of Applied Cell Sciences, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran|Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Mahdi Hatamipour

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Behrang Alani

Department of Applied Cell Sciences, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran

Hossein Nikzad

Anatomical Sciences Research Center, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Fan Q CZ, Wang C, Liu Z. Toward biomaterials for ...
  • Van der Burg SH, Arens R, Ossendorp F, van Hall ...
  • Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune ...
  • Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, ...
  • Gajewski TF. The next hurdle in cancer immunotherapy: Overcoming the ...
  • Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, ...
  • Chowdhury PS, Chamoto K, Honjo T. Combination therapy strategies for ...
  • Byrne KT, Cote AL, Zhang P, Steinberg SM, Guo Y, ...
  • Dougan M DG. Immune therapy for cancer. Annu Rev Immunol ...
  • Smith DM, Simon JK, Baker JR, Jr. Applications of nanotechnology ...
  • Korsholm KS, Andersen PL, Christensen D. Cationic liposomal vaccine adjuvants ...
  • Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, ...
  • Oussoren C, Zuidema J, Crommelin DJ, Storm G. Lymphatic uptake ...
  • Christensen D, Korsholm KS, Rosenkrands I, Lindenstrom T, Andersen P, ...
  • Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD, ...
  • Yan W, Chen W, Huang L. Mechanism of adjuvant activity ...
  • Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune ...
  • Khazanov E, Simberg D, Barenholz Y. Lipoplexes prepared from cationic ...
  • Whitmore MM, Li S, Falo L, Jr., Huang L. Systemic ...
  • Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best ...
  • Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, ...
  • Klinman DM, Currie D, Gursel I, Verthelyi D. Use of ...
  • Krieg AM. CpG motifs in bacterial DNA and their immune ...
  • Puangpetch A, Anderson R, Huang YY, Sermswan RW, Chaicumpa W, ...
  • Davila E, Kennedy R, Celis E. Generation of antitumor immunity ...
  • Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, ...
  • Wang S, Campos J, Gallotta M, Gong M, Crain C, ...
  • Gholizadeh Z, Tavakkol-Afshari J, Nikpoor AR, Jalali SA, Jaafari MR. ...
  • Pappalardo F, Pennisi M, Ricupito A, Topputo F, Bellone M. ...
  • Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal ...
  • Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, ...
  • Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, ...
  • Blake SJ, Ching AL, Kenna TJ, Galea R, Large J, ...
  • Shindo Y, Yoshimura K, Kuramasu A, Watanabe Y, Ito H, ...
  • Danciu C, Oprean C, Coricovac DE, Andreea C, Cimpean A, ...
  • Satterlee AB, Rojas JD, Dayton PA, Huang L. Enhancing Nanoparticle ...
  • Kalli F, Machiorlatti R, Battaglia F, Parodi A, Conteduca G, ...
  • Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, ...
  • Prezado Y, Sarun S, Gil S, Deman P, Bouchet A, ...
  • Mishina H, Watanabe K, Tamaru S, Watanabe Y, Fujioka D, ...
  • Razazan A, Behravan J, Arab A, Barati N, Arabi L, ...
  • Vasievich EA, Chen W, Huang L. Enantiospecific adjuvant activity of ...
  • Zeng Q, Jiang H, Wang T, Zhang Z, Gong T, ...
  • Li SY, Liu Y, Xu CF, Shen S, Sun R, ...
  • Chen S, Lee LF, Fisher TS, Jessen B, Elliott M, ...
  • Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and ...
  • McDermott DF, Atkins MB. PD-1 as a potential target in ...
  • Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway ...
  • Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and ...
  • Chen DS, Mellman I. Elements of cancer immunity and the ...
  • Chen W, Yan W, Huang L. A simple but effective ...
  • Saremi SS, Shahryari M, Ghoorchian R, Eshaghian H, Jalali SA, ...
  • Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, ...
  • Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrom T, Agger EM, ...
  • Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrom T, Agger EM, ...
  • Knutson KL, Disis ML. Tumor antigen-specific T helper cells in ...
  • Gao J, Ochyl LJ, Yang E, Moon JJ. Cationic liposomes ...
  • Shahum E, Therien HM. Liposomal adjuvanticity: effect of encapsulation and ...
  • Shariat S, Badiee A, Amir Jalali S, Mansourian M, Alireza ...
  • Chen W, Huang L. Induction of cytotoxic T-lymphocytes and antitumor ...
  • Shariat S, Badiee A, Jalali SA, Mansourian M, Yazdani M, ...
  • Rastakhiz S, Yazdani M, Shariat S, Arab A, Momtazi-Borojeni AA, ...
  • Farzad N, Barati N, Momtazi-Borojeni AA, Yazdani M, Arab A, ...
  • Zamani P, Navashenaq JG, Nikpoor AR, Hatamipour M, Oskuee RK, ...
  • Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using ...
  • Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: ...
  • Joshi MD, Unger WJ, Storm G, van Kooyk Y, Mastrobattista ...
  • Bauer M, Redecke V, Ellwart JW, Scherer B, Kremer JP, ...
  • Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. ...
  • Dresch C, Leverrier Y, Marvel J, Shortman K. Development of ...
  • Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis ...
  • Jalali SA, Sankian M, Tavakkol-Afshari J, Jaafari MR. Induction of ...
  • Ghaffari-Nazari H, Tavakkol-Afshari J, Jaafari MR, Tahaghoghi-Hajghorbani S, Masoumi E, ...
  • Tahaghoghi-Hajghorbani S, Tavakkol-Afshari J, Jaafari MR, Ghaffari-Nazari H, Masoumi E, ...
  • Jeanbart L, Ballester M, de Titta A, Corthesy P, Romero ...
  • Xu Z, Ramishetti S, Tseng YC, Guo S, Wang Y, ...
  • Mansourian M, Badiee A, Jalali SA, Shariat S, Yazdani M, ...
  • نمایش کامل مراجع